The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 29, 2010
Filed:
May. 31, 2005
John W. Shiver, Chalfont, PA (US);
Michael D. Miller, Chalfont, PA (US);
Romas Geleziunas, Doylestown, PA (US);
Daria J. Hazuda, Doylestown, PA (US);
Peter S. Kim, Bryn Mawr, PA (US);
Debra M. Eckert, Salt Lake City, UT (US);
Michael J. Root, Boston, MA (US);
Simon N. Lennard, Melbourn, GB;
Elisabetta Bianchi, Via Sabotino, IT;
John W. Shiver, Chalfont, PA (US);
Michael D. Miller, Chalfont, PA (US);
Romas Geleziunas, Doylestown, PA (US);
Daria J. Hazuda, Doylestown, PA (US);
Peter S. Kim, Bryn Mawr, PA (US);
Debra M. Eckert, Salt Lake City, UT (US);
Michael J. Root, Boston, MA (US);
Simon N. Lennard, Melbourn, GB;
Elisabetta Bianchi, Via Sabotino, IT;
Merck & Co., Inc., Rahway, NJ (US);
Whitehead Insitute of Biomedical Research, Cambridge, MA (US);
MedImmune Limited, Cambridge, Cambridgeshire, GB;
Istitute di Ricerche di Biologia Molecolare P. Angeletti S.p.A., Pomesia, Rome, IT;
Abstract
Human scFvs are disclosed which interact with a conformational epitope along the pre-hairpin, N-helix coiled coil structure within the heptad repeat 1 (HR1) region of gp41 of HIV. These antibodies, as well as IgG conversions, are shown to neutralize diverse HIV isolates. Isolated nucleic acid molecules are also disclosed which encode relevant portions of these antibodies, as well as the purified forms of the expressed antibodies or relevant antibody fragments, such as Vand Vchains. The antibody compositions disclosed within this specification may provide for a therapeutic treatment against HIV infection by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV infection. These antibodies will also be useful in assays to identify HIV antiviral compounds as well as allowing for the identification of candidate HIV vaccines, such as HIV peptide vaccines.